Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

References

• Teras LR , DeSantis CE , Cerhan JR , Morton LM , Jemal A , Flowers CR . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin . 2016;66(6):443–459. doi:10.3322/caac.21357 27618563
   PubMed Web of Science ®Google Scholar
• Sim J , Takayama T , Cho J , et al. Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016: an observational study. Medicine . 2019;98(45):e17641. doi:10.1097/MD.0000000000017641 31702615
   PubMed Web of Science ®Google Scholar
• Cho I , Yoon N , Hyeon J , et al. Comparison of the lymph2Cx assay and Hans algorithm in determining the cell-of-origin of diffuse large B-cell lymphomas, not otherwise specified. Appl Immunohistochem Mol Morphol . 2020;28(10):731–740. doi:10.1097/PAI.0000000000000843 32287077
   PubMedGoogle Scholar
• Wright G , Tan B , Rosenwald A , Hurt EH , Wiestner A , Staudt LM . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A . 2003;100(17):9991–9996. doi:10.1073/pnas.1732008100 12900505
   PubMed Web of Science ®Google Scholar
• Sehn LH , Donaldson J , Chhanabhai M , et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol . 2005;23(22):5027–5033. doi:10.1200/JCO.2005.09.137 15955905
   PubMed Web of Science ®Google Scholar
• Coiffier B , Thieblemont C , Van Den Neste E , et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood . 2010;116(12):2040–2045. doi:10.1182/blood-2010-03-276246 20548096
   PubMed Web of Science ®Google Scholar
• Maurer MJ , Ghesquieres H , Jais JP , et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol . 2014;32(10):1066–1073. doi:10.1200/JCO.2013.51.5866 24550425
   PubMed Web of Science ®Google Scholar
• Hong J , Kim SJ , Chang MH , et al. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget . 2017;8(54):92171–92182. doi:10.18632/oncotarget.20988 29190906
   PubMedGoogle Scholar
• Kim SJ , Hong JS , Chang MH , et al. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: results of a multicenter prospective cohort study. Oncotarget . 2016;7(44):72033–72043. doi:10.18632/oncotarget.12459 27713132
   PubMedGoogle Scholar
• Gisselbrecht C , Glass B , Mounier N , et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol . 2010;28(27):4184–4190. doi:10.1200/JCO.2010.28.1618 20660832
   PubMed Web of Science ®Google Scholar
• Hitz F , Connors JM , Gascoyne RD , et al. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol . 2015;94(11):1839–1843. doi:10.1007/s00277-015-2467-z 26246466
   PubMed Web of Science ®Google Scholar
• Salles GA , Pettengell R , Cordoba R , Długosz-Danecka M , Jurczak W , Tilly H . Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leuk Lymphoma . 2019;60(7):1610–1625. doi:10.1080/10428194.2018.1564828 30702000
   PubMed Web of Science ®Google Scholar
• Wu L , Adams M , Carter T , et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res . 2008;14(14):4650–4657. doi:10.1158/1078-0432.CCR-07-4405 18628480
   PubMed Web of Science ®Google Scholar
• Ramsay AG , Clear AJ , Kelly G , et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood . 2009;114(21):4713–4720. doi:10.1182/blood-2009-04-217687 19786615
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A , Mendy D , Ito T , et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia . 2012;26(11):2326–2335. doi:10.1038/leu.2012.119 22552008
   PubMed Web of Science ®Google Scholar
• Gandhi AK , Kang J , Havens CG , et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol . 2014;164(6):811–821. doi:10.1111/bjh.12708 24328678
   PubMed Web of Science ®Google Scholar
• Wiernik PH , Lossos IS , Tuscano JM , et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol . 2008;26(30):4952–4957. doi:10.1200/JCO.2007.15.3429 18606983
   PubMed Web of Science ®Google Scholar
• Witzig TE , Vose JM , Zinzani PL , et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol . 2011;22(7):1622–1627. doi:10.1093/annonc/mdq626 21228334
   PubMed Web of Science ®Google Scholar
• Broccoli A , Casadei B , Chiappella A , et al. Lenalidomide in pretreated patients with diffuse large B-cell lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Oncologist . 2019;24(9):1246–1252. doi:10.1634/theoncologist.2018-0603 30940746
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ , Reddy N , Holkova B , Ottman E , Czuczman MS . Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res . 2005;11(16):5984–5992. doi:10.1158/1078-0432.CCR-05-0577 16115943
   PubMed Web of Science ®Google Scholar
• Zinzani PL , Pellegrini C , Gandolfi L , et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a Phase 2 trial. Clin Lymphoma Myeloma Leuk . 2011;11(6):462–466. doi:10.1016/j.clml.2011.02.001 21859554
   PubMed Web of Science ®Google Scholar
• Wang M , Fowler N , Wagner-Bartak N , et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia . 2013;27(9):1902–1909. doi:10.1038/leu.2013.95 23545991
   PubMed Web of Science ®Google Scholar
• Swerdlow SH , Campo E , Harris NL , et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues . 4th ed. 2017.
   Google Scholar
• Cheson BD , Fisher RI , Barrington SF , et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol . 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800 25113753
   PubMed Web of Science ®Google Scholar
• Hyeon J , Lee B , Shin SH , et al. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod Pathol . 2018;31(9):1418–1428. doi:10.1038/s41379-018-0064-0 29765142
   PubMed Web of Science ®Google Scholar
• Shin HT , Choi YL , Yun JW , et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat Commun . 2017;8(1):1377. doi:10.1038/s41467-017-01470-y 29123093
   PubMed Web of Science ®Google Scholar
• Wilm A , Aw PP , Bertrand D , et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res . 2012;40(22):11189–11201. doi:10.1093/nar/gks918 23066108
   PubMed Web of Science ®Google Scholar
• Cibulskis K , Lawrence MS , Carter SL , et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol . 2013;31(3):213–219. doi:10.1038/nbt.2514 23396013
   PubMed Web of Science ®Google Scholar
• Ivanov V , Coso D , Chetaille B , et al. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma . 2014;55(11):2508–2513. doi:10.3109/10428194.2014.889822 24506467
   PubMed Web of Science ®Google Scholar
• Ghesquieres H , Chevrier M , Laadhari M , et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA)†. Ann Oncol . 2019;30(4):621–628. doi:10.1093/annonc/mdz032 30698644
   PubMed Web of Science ®Google Scholar
• Yang Y , Shaffer AL , Emre NC , et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell . 2012;21(6):723–737. doi:10.1016/j.ccr.2012.05.024 22698399
   PubMed Web of Science ®Google Scholar
• Nowakowski GS , LaPlant B , Macon WR , et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol . 2015;33(3):251–257. doi:10.1200/JCO.2014.55.5714 25135992
   PubMed Web of Science ®Google Scholar
• Vitolo U , Chiappella A , Franceschetti S , et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol . 2014;15(7):730–737. doi:10.1016/S1470-2045(14)70191-3 24831981
   PubMed Web of Science ®Google Scholar
• Nowakowski GS , Hong F , Scott DW , et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol . 2021;JCO2001375.
   Web of Science ®Google Scholar
• Nowakowski GS , Chiappella A , Gascoyne RD , et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol . 2021;39(12):1317–1328. doi:10.1200/JCO.20.01366 33621109
   PubMed Web of Science ®Google Scholar
• Goy A , Ramchandren R , Ghosh N , et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL. Blood . 2019;134(13):1024–1036. doi:10.1182/blood.2018891598 31331917
   PubMed Web of Science ®Google Scholar
• Sethi T , Kovach AE , Mason EF , et al. Combination of nivolumab, lenalidomide and rituximab in relapsed/refractory non-germinal center diffuse large B cell lymphoma: results from a dose-escalation cohort. Blood . 2019;134(Supplement_1):4100. doi:10.1182/blood-2019-129634
   Web of Science ®Google Scholar